Siravegna and colleagues exploited the circulating tumor DNA to genotype colorectal tumors and tracked clonal evolution during treatment with EGFR-specific antibodies, discovering that the percentage of mutated KRAS clones declines in blood when EGFR-specific antibodies are withdrawn. The gene discussed is EGFR; the disease is neoplasm.